FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2546779013> ?p ?o ?g. }

• W2546779013 endingPage "3979" @default.
• W2546779013 startingPage "3979" @default.
• W2546779013 abstract "Abstract BACKGROUND: It has been recently shown that nivolumab, a programmed death 1 (PD-1) blocking antibody, had substantial therapeutic activity and an acceptable safety profile in patients with relapsed or refractory Hodgkin's lymphoma (HL). To our knowledge, this drug has never been tested after allogeneic stem cell transplantation (allo-SCT) mainly because PD-1-blocking strategy may substantially increase the risk of Graft Versus Host Disease (GVHD). Nevertheless, some studies suggested that Reed-Sternberg cells exploit the PD-1 pathway to evade immune detection, possibly explaining why some patients resist to graft-versus-lymphoma effect. PATIENTS AND METHODS: We retrospectively assessed the efficacy and toxicity of nivolumab as a single agent in 12 HL patients relapsing after allo-SCT. All patients had progressive disease at the nivolumab initiation. The dose was 3 mg/kg of body weight every 2 weeks. The median of previous systemic therapies was 9 (range 7-11), including allo-SCT. Patients were required to be off immune suppression for more than 4 weeks prior to nivolumab initiation, with no history of grades III-IV acute or extensive chronic GVHD. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria for AEs (version 4.0). Efficacy was assessed by physical examination before each infusion and per IWG guidelines (Cheson 2007) after four injections of nivolumab. RESULTS: Eight out of 12 patients were evaluable at the time of submission. Median age at time of transplant was 31 (range 28-42) and median time from allo-SCT to study treatment was 11 months (range 3 - 122). Eight patients had related donors and 4 patients had unrelated donors including one haploidentical transplantation. Best response before allo-SCT was RP in 8 patients and RC in 4 patients. Allo-SCT improved response in only 2 patients. Six patients had received therapy for HL progression/relapse post allo-SCT, including donor lymphocyte infusions (n=4). Median number of injection of nivolumab was 4 (range 1-10). Acute GVHD occurred in 2 patients after 1 injection (grade III skin acute GVHD) and 2 injections (grade IV skin acute GVHD) of nivolumab. In one patient, GVHD responded quickly to corticosteroids therapy. The patient who received haplo-identical allo-SCT presented with corticosteroid-refractory grade IV skin GVHD reversed after several extracorporeal photopheresis sessions. Both patients had prior history of grade II acute GVHD in the three months before nivolumab administration and treatment was stopped. Nivolumab did not modify chimerism. The only serious hematological adverse events were grade 4 neutropenia (1 patient) and grade 3 thrombocytopenia (1 patient). No other non-hematological adverse event was observed except a grade 2 cerebellar ataxia. With a median follow-up of 60 days post nivolumab initiation, 1 patient discontinued due to progressive disease, 2 patients due to acute GVHD and 9 patients remain on nivolumab. In our preliminary analysis of efficacy, 7 out of the 8 (87.5%) patients evaluable for response had clinical benefit, with 4 achieving partial response and 3 in complete response according to Cheson 2007 criteria. Of note, one of the patient developing acute GVHD post nivolumab achieved partial response. No data for the other patient presenting with acute GVHD after treatment was available at the time of analysis. CONCLUSIONS: Our preliminary results suggest that nivolumab is effective with manageable toxicity in patients with relapsed or refractory Hodgkin's lymphoma after allo-SCT. These encouraging results emphasize the need to delineate indications and perform prospective protocols. Disclosures Morschhauser: Genentech Inc./Roche: Other: Advisory boards." @default.
• W2546779013 created "2016-11-11" @default.
• W2546779013 creator A5010158325 @default.
• W2546779013 creator A5013649293 @default.
• W2546779013 creator A5013925872 @default.
• W2546779013 creator A5015559721 @default.
• W2546779013 creator A5031216970 @default.
• W2546779013 creator A5045486705 @default.
• W2546779013 creator A5045751060 @default.
• W2546779013 creator A5050987906 @default.
• W2546779013 creator A5051605599 @default.
• W2546779013 creator A5055596354 @default.
• W2546779013 creator A5056514957 @default.
• W2546779013 creator A5068452218 @default.
• W2546779013 creator A5074161015 @default.
• W2546779013 creator A5078342005 @default.
• W2546779013 date "2015-12-03" @default.
• W2546779013 modified "2023-09-30" @default.
• W2546779013 title "Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC" @default.
• W2546779013 doi "https://doi.org/10.1182/blood.v126.23.3979.3979" @default.
• W2546779013 hasPublicationYear "2015" @default.
• W2546779013 type Work @default.
• W2546779013 sameAs 2546779013 @default.
• W2546779013 citedByCount "28" @default.
• W2546779013 countsByYear W25467790132016 @default.
• W2546779013 countsByYear W25467790132017 @default.
• W2546779013 countsByYear W25467790132018 @default.
• W2546779013 countsByYear W25467790132019 @default.
• W2546779013 countsByYear W25467790132021 @default.
• W2546779013 countsByYear W25467790132023 @default.
• W2546779013 crossrefType "journal-article" @default.
• W2546779013 hasAuthorship W2546779013A5010158325 @default.
• W2546779013 hasAuthorship W2546779013A5013649293 @default.
• W2546779013 hasAuthorship W2546779013A5013925872 @default.
• W2546779013 hasAuthorship W2546779013A5015559721 @default.
• W2546779013 hasAuthorship W2546779013A5031216970 @default.
• W2546779013 hasAuthorship W2546779013A5045486705 @default.
• W2546779013 hasAuthorship W2546779013A5045751060 @default.
• W2546779013 hasAuthorship W2546779013A5050987906 @default.
• W2546779013 hasAuthorship W2546779013A5051605599 @default.
• W2546779013 hasAuthorship W2546779013A5055596354 @default.
• W2546779013 hasAuthorship W2546779013A5056514957 @default.
• W2546779013 hasAuthorship W2546779013A5068452218 @default.
• W2546779013 hasAuthorship W2546779013A5074161015 @default.
• W2546779013 hasAuthorship W2546779013A5078342005 @default.
• W2546779013 hasBestOaLocation W25467790131 @default.
• W2546779013 hasConcept C121332964 @default.
• W2546779013 hasConcept C121608353 @default.
• W2546779013 hasConcept C126322002 @default.
• W2546779013 hasConcept C141071460 @default.
• W2546779013 hasConcept C142424586 @default.
• W2546779013 hasConcept C143998085 @default.
• W2546779013 hasConcept C197934379 @default.
• W2546779013 hasConcept C2776694085 @default.
• W2546779013 hasConcept C2777408962 @default.
• W2546779013 hasConcept C2777701055 @default.
• W2546779013 hasConcept C2778822529 @default.
• W2546779013 hasConcept C2779338263 @default.
• W2546779013 hasConcept C2780030458 @default.
• W2546779013 hasConcept C2911091166 @default.
• W2546779013 hasConcept C71924100 @default.
• W2546779013 hasConcept C87355193 @default.
• W2546779013 hasConcept C90924648 @default.
• W2546779013 hasConceptScore W2546779013C121332964 @default.
• W2546779013 hasConceptScore W2546779013C121608353 @default.
• W2546779013 hasConceptScore W2546779013C126322002 @default.
• W2546779013 hasConceptScore W2546779013C141071460 @default.
• W2546779013 hasConceptScore W2546779013C142424586 @default.
• W2546779013 hasConceptScore W2546779013C143998085 @default.
• W2546779013 hasConceptScore W2546779013C197934379 @default.
• W2546779013 hasConceptScore W2546779013C2776694085 @default.
• W2546779013 hasConceptScore W2546779013C2777408962 @default.
• W2546779013 hasConceptScore W2546779013C2777701055 @default.
• W2546779013 hasConceptScore W2546779013C2778822529 @default.
• W2546779013 hasConceptScore W2546779013C2779338263 @default.
• W2546779013 hasConceptScore W2546779013C2780030458 @default.
• W2546779013 hasConceptScore W2546779013C2911091166 @default.
• W2546779013 hasConceptScore W2546779013C71924100 @default.
• W2546779013 hasConceptScore W2546779013C87355193 @default.
• W2546779013 hasConceptScore W2546779013C90924648 @default.
• W2546779013 hasIssue "23" @default.
• W2546779013 hasLocation W25467790131 @default.
• W2546779013 hasLocation W25467790132 @default.
• W2546779013 hasOpenAccess W2546779013 @default.
• W2546779013 hasPrimaryLocation W25467790131 @default.
• W2546779013 hasRelatedWork W2003938723 @default.
• W2546779013 hasRelatedWork W2047967234 @default.
• W2546779013 hasRelatedWork W2351476339 @default.
• W2546779013 hasRelatedWork W2351796763 @default.
• W2546779013 hasRelatedWork W2439875401 @default.
• W2546779013 hasRelatedWork W2586113026 @default.
• W2546779013 hasRelatedWork W2738397398 @default.
• W2546779013 hasRelatedWork W2914827752 @default.
• W2546779013 hasRelatedWork W2972494744 @default.
• W2546779013 hasRelatedWork W3090664821 @default.
• W2546779013 hasVolume "126" @default.
• W2546779013 isParatext "false" @default.
• W2546779013 isRetracted "false" @default.

• next